What is the MTHFR gene mutation, why is treatment indicated, and what are the risks if it is left untreated?

MTHFR Gene Mutation: No Routine Treatment Needed for Common Variants

The common MTHFR gene variants (c.665C>T and c.1286A>C) do NOT require treatment, and routine testing for these variants is explicitly NOT recommended by major medical organizations. 1

What is MTHFR?

The MTHFR gene encodes methylenetetrahydrofolate reductase, an enzyme that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. This converted form is crucial for remethylating homocysteine to methionine, affecting nucleic acid and protein synthesis 1.

Two Distinct Clinical Entities

There is critical confusion in the public about MTHFR that must be clarified:

1. Common MTHFR Polymorphisms (NOT a disease):

• The two well-known variants are c.665C>T (p.Ala222Val, also called C677T) and c.1286A>C (p.Glu429Ala)
• These are extremely common in the population (heterozygous in 30-40%, homozygous in 10-15%) 2
• They reduce enzyme activity and were previously hypothesized to cause mild hyperhomocysteinemia

2. Severe MTHFR Deficiency (rare genetic disease):

• Caused by rare deleterious mutations (over 109 different mutations identified) 3
• Presents with severe neurological symptoms, developmental delay, seizures, often in infancy or early childhood 3, 4, 5, 6
• This IS a true medical emergency requiring immediate treatment

Why Treatment is NOT Needed for Common Variants

The American College of Medical Genetics and Genomics (ACMG) explicitly states that routine MTHFR variant testing should NOT be ordered for:

• Thrombophilia evaluation
• Recurrent pregnancy loss
• Adverse perinatal events
• Reproductive carrier screening 1

The Evidence Against Treatment

Recent meta-analyses have shown no significant association between common MTHFR variants and:

• Venous thromboembolism (VTE)
• Coronary heart disease
• Recurrent pregnancy loss 1

This position is supported by:

• American College of Obstetricians and Gynecologists (ACOG)
• British Committee for Standards in Haematology
• British Society for Haematology 1

Critical distinction: The MTHFR C677T variant by itself is NOT associated with arterial or venous thrombosis in the absence of actual hyperhomocysteinemia 2, 7. The variant increases risk for hyperhomocysteinemia, but the variant alone without elevated homocysteine levels does not require treatment.

What Happens If Common MTHFR Variants Are "Not Treated"

Nothing adverse happens because these common variants do not cause disease requiring treatment. The previous hypothesis that reduced MTHFR enzyme activity leads to clinically significant problems has been disproven by recent meta-analyses 1.

When to Actually Measure and Treat

Measure plasma homocysteine levels (not MTHFR genotype) if:

• Patient has unexplained venous or arterial thrombosis
• Strong family history of early cardiovascular disease
• Recurrent pregnancy loss with other causes excluded

Treatment is indicated for actual hyperhomocysteinemia (elevated homocysteine levels), NOT for MTHFR variants:

Moderate hyperhomocysteinemia (15-30 μmol/L):

• Folic acid 400 μg/day (achieves 25-30% reduction)
• Add vitamin B12 (0.02-1 mg/day) for additional 7% reduction 8
• Address underlying causes: folate/B12 deficiency, hypothyroidism, renal dysfunction

Intermediate hyperhomocysteinemia (30-100 μmol/L):

• Higher dose folate supplementation
• Vitamin B12 and B6 combination
• Treat underlying cobalamin or folate deficiency 8

For MTHFR 677TT genotype with elevated homocysteine:

• Consider oral 5-methyltetrahydrofolate (the active form) instead of folic acid, as this bypasses the need for MTHFR enzyme conversion 8

Severe MTHFR Deficiency: When Treatment IS Critical

This is a completely different condition from common MTHFR variants. Severe MTHFR deficiency presents with:

• Severe hyperhomocysteinemia (often >100 μmol/L)
• Low methionine levels
• Neurological symptoms: developmental delay, seizures, intellectual disability, microcephaly
• Onset typically in infancy or early childhood 3, 4, 5, 6

Treatment for Severe MTHFR Deficiency

First-line therapy: 9

• Betaine (first-line for MTHFR deficiency)
• Hydroxocobalamin (parenteral, high-dose >0.35 mg/kg/day for cobalamin-related defects)
• Folinic acid or 5-methyltetrahydrofolate
• Low-methionine diet with cysteine supplementation 8, 9

Goals:

• Keep homocysteine and methionine as close to normal as achievable
• Early treatment (ideally through newborn screening) improves outcomes 9, 6

What Happens Without Treatment in Severe Deficiency

Untreated severe MTHFR deficiency leads to:

• Progressive neurological deterioration
• Intellectual disability
• Seizures
• Thromboembolic events (both arterial and venous)
• Death in severe early-onset cases 3, 4, 5

Common Pitfalls to Avoid

1. Do not order MTHFR genetic testing routinely - it has no clinical utility for common variants 1

2. If concerned about thrombosis risk, measure plasma homocysteine levels directly rather than testing for MTHFR variants 2, 8

3. Do not treat MTHFR variants; treat elevated homocysteine levels if present 8

4. Recognize that most people with MTHFR variants have normal homocysteine levels and require no intervention

5. For patients with MTHFR 677TT genotype and elevated homocysteine, use 5-methyltetrahydrofolate instead of folic acid for more effective treatment 8

6. Distinguish between common polymorphisms (benign) and rare severe mutations (life-threatening) 3, 10